表紙
市場調査レポート

特許失効予定の農薬活性成分の概略

Guide of Coming Off-patent Agrochemical Active Ingredients Edition 2

発行 CCM 商品コード 331529
出版日 ページ情報 英文 161 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
特許失効予定の農薬活性成分の概略 Guide of Coming Off-patent Agrochemical Active Ingredients Edition 2
出版日: 2015年05月13日 ページ情報: 英文 161 Pages
概要

世界の農薬市場では、登録品目のうち75%がジェネリック農薬となっています。2015〜2020年に、35種類の農薬 (除草剤11種類、殺虫剤8種類、殺菌剤16種類) が特許期間の満了を迎えます。さらに、2023年までに世界全体で166件もの農薬関連の特許が失効する予定です。これにより、110億米ドルもの市場価値の創出が期待されています。農薬の新規開発と比べると、特許が満了した農薬は低コスト・低リスクで開発でき、しかも相当の利益率を見込めます。つまり、巨大な商業的価値が存在するわけです。

当レポートでは、今後5年間で特許が満了する予定の農薬に関する情報を取りまとめ、各製品のプロファイル (基本情報、沿革、合成経路、用途、安全性など) および特許・登録情報を調査すると共に、業界全体の特許満了状況や、主要国における主力製品の登録状況といった情報を整理してお届けいたします。

調査手法・範囲

第1章 特許満了予定の除草剤のプロファイル

  • フルセトフルスホン
  • フルフェンプルエチル
  • ホラムスルフロン
  • メタミホップ
  • オルトスルファムロン
  • ペノキススラム
  • ピノキサデン
  • プロポキシカルバゾン
  • テンボトリオン
  • チエンカルバゾンメチル
  • トプラメゾン

第2章 特許満了予定の殺虫剤のプロファイル

  • ビストリフルロン
  • クロチアニジン
  • エチプロル
  • フルベンジアミド
  • メトフルトリン
  • ピリダリル
  • ピリフルキナゾン
  • スピロテトラマト

第3章 特許満了予定の殺菌剤のプロファイル

  • アミスルブロム
  • ベナラキシル-M
  • ベンチアバリカルブイソプロピル
  • シフルフェナミド
  • ジモキシストロビン
  • フルオピコリド
  • フルオキサストロビン
  • イソチアニル
  • メタラキシル-M
  • メトラフェノン
  • オリサストロビン
  • ペンチオピラド
  • プロチオコナゾール
  • ピラクロストロビン
  • シルチオファム
  • バリフェナレート

図表一覧

目次

In the global pesticide market, generic pesticides accounted for 75% in the terms of registration quantity. During the time from 2015 to 2020, patents of 35 pesticide varieties will be expired (including 11 kinds of herbicides, 8 kinds of insecticides and 16 kinds of fungicides). What's more, by 2023, 166 kinds of pesticide-related patents will be expired all over the world, and it is expected that an added market value will reach USD11 billion. Compared with developing new varieties of pesticides, to develop the pesticides which have been expired will not only cost less and have lower risk, but also has considerable profits. In a word, it will be a huge market with tremendous commercial value.

In this report, CCM focuses on the patent products including basic information, history, synthesis route, application, physical & safety data, patent information and registration information.

Through this report, you can:

  • Gain an overview of general situation of the coming off-patent products from 2015 to 2020;
  • Know the registration situation of the hot products of agricultural giants in the main agricultural countries;

This report is a good guide for other pesticide companies who are interested in the commercial development of these coming off-patent products.

Table of Contents

Methodology and scope

1. Profiles of coming off-patent herbicides

  • 1-1. Flucetosulfuron
  • 1-2. Flufenpyr-ethyl
  • 1-3. Foramsulfuron
  • 1-4. Metamifop
  • 1-5. Orthosulfamuron
  • 1-6. Penoxsulam
  • 1-7. Pinoxaden
  • 1-8. Propoxycarbazone
  • 1-9. Tembotrione
  • 1-10. Thiencarbazone-methyl
  • 1-11. Topramezone

2. Profiles of coming off-patent insecticides

  • 2-1. Bistrifluron
  • 2-2. Clothianidin
  • 2-3. Ethiprole
  • 2-4. Flubendiamide
  • 2-5. Metofluthrin
  • 2-6. Pyridalyl
  • 2-7. Pyrifluquinazon
  • 2-8. Spirotetramat

3. Profiles of coming off-patent fungicides

  • 3-1. Amisulbrom
  • 3-2. Benalaxyl-M
  • 3-3. Benthiavalicarb-isopropyl
  • 3-4. Cyflufenamid
  • 3-5. Dimoxystrobin
  • 3-6. Fluopicolide
  • 3-7. Fluoxastrobin
  • 3-8. Isotianil
  • 3-9. Metalaxyl-M
  • 3-10. Metrafenone
  • 3-11. Orysastrobin
  • 3-12. Penthiopyrad
  • 3-13. Prothioconazole
  • 3-14. Pyraclostrobin
  • 3-15. Silthiofam
  • 3-16. Valifenalate

List of Tables:

  • Table 1.1-1: Patent information of flucetosulfuron in some countries/regions, as of April 2015
  • Table 1.1-2: Registration information of flucetosulfuron in China, as of April 2015
  • Table 1.2-1: Patent information of flufenpyr-ethyl in some countries/regions, as of April 2015
  • Table 1.3-1: Patent information of foramsulfuron in some countries/regions, as of April 2015
  • Table 1.3-2: Registration information of foramsulfuron in Argentina, as of April 2015
  • Table 1.3-3: Registration information of foramsulfuron in Australia, as of April 2015
  • Table 1.3-4: Registration information of foramsulfuron in Belgium, as of April 2015
  • Table 1.3-5: Registration information of foramsulfuron in Canada, as of April 2015
  • Table 1.3-6: Registration information of foramsulfuron in Chile, as of April 2015
  • Table 1.3-7: Registration information of foramsulfuron in Denmark, as of April 2015
  • Table 1.3-8: Registration information of foramsulfuron in France, as of April 2015
  • Table 1.3-9: Registration information of foramsulfuron in Greece, as of April 2015
  • Table 1.3-10: Registration information of foramsulfuron in the Netherlands, as of April 2015
  • Table 1.3-11: Registration information of foramsulfuron in Switzerland, as of April 2015
  • Table 1.3-12: Registration information of foramsulfuron in Uruguay, as of April 2015
  • Table 1.4-1: Patent information of metamifop in some countries/regions, as of April 2015
  • Table 1.4-2: Registration information of metamifop in China, as of April 2015
  • Table 1.5-1: Patent information of orthosulfamuron in some countries/regions, as of April 2015
  • Table 1.5-2: Registration information of orthosulfamuron in Brazil, as of April 2015
  • Table 1.5-3: Registration information of orthosulfamuron in China, as of April 2015
  • Table 1.6-1: Patent information of penoxsulam in some countries/regions, as of April 2015
  • Table 1.6-2: Registration information of penoxsulam in Argentina, as of April 2015
  • Table 1.6-3: Registration information of penoxsulam in Brazil, as of April 2015
  • Table 1.6-4: Registration information of penoxsulam in Chile, as of April 2015
  • Table 1.6-5: Registration information of penoxsulam in China, as of April 2015
  • Table 1.6-6: Registration information of penoxsulam in France, as of April 2015
  • Table 1.6-7: Registration information of penoxsulam in Greece, as of April 2015
  • Table 1.6-8: Registration information of penoxsulam in Switzerlands, as of April 2015
  • Table 1.6-9: Registration information of penoxsulam in Uruguay, as of April 2015
  • Table 1.7-1: Patent information of pinoxaden in some countries/regions, as of April 2015
  • Table 1.7-2: Registration information of pinoxaden in Argentina, as of April 2015
  • Table 1.7-3: Registration information of pinoxaden in Australia, as of April 2015
  • Table 1.7-4: Registration information of pinoxaden in Belgium, as of April 2015
  • Table 1.7-5: Registration information of pinoxaden in Canada, as of April 2015
  • Table 1.7-6: Registration information of pinoxaden in Chile, as of April 2015
  • Table 1.7-7: Registration information of pinoxaden in China, as of April 2015
  • Table 1.7-8: Registration information of pinoxaden in Finland, as of April 2015
  • Table 1.7-9: Registration information of pinoxaden in France, as of April 2015
  • Table 1.7-10: Registration iunformation of pinoxaden in Greece, as of April 2015
  • Table 1.7-11: Registration information of pinoxaden in the Netherlands, as of April 2015
  • Table 1.7-12: Registration information of pinoxaden in Switzerland, as of April 2015
  • Table 1.7-13: Registration information of pinoxaden in Uruguay, as of April 2015
  • Table 1.8-1: Patent information of propoxycarbazone in some countries/regions, as of April 2015
  • Table 1.8-2: Registration information of propoxycarbazone in Belgium, as of April 2015
  • Table 1.8-3: Registration information of propoxycarbazone in Finland, as of April 2015
  • Table 1.8-4: Registration information of propoxycarbazone in France, as of April 2015
  • Table 1.8-5: Registration information of propoxycarbazone in Greece, as of April 2015
  • Table 1.9-1: Patent information of tembotrione in some countries/regions, as of April 2015
  • Table 1.9-2: Registration information of tembotrione in Belgium, as of April 2015
  • Table 1.9-3: Registration information of tembotrione in Canada, as of April 2015
  • Table 1.9-4: Registration information of tembotrione in Chile, as of April 2015
  • Table 1.9-5: Registration information of tembotrione in France, as of April 2015
  • Table 1.9-6: Registration information of tembotrione in Greece, as of April 2015
  • Table 1.9-7: Registration information of tembotrione in the Netherlands, as of April 2015
  • Table 1.9-8: Registration information of tembotrione in Switzerland, as of April 2015
  • Table 1.10-1: Patent information of thiencarbazone-methyl in some countries/regions, as of April 2015
  • Table 1.10-2: Registration information of thiencarbazone-methyl in Belgium, as of April 2015
  • Table 1.10-3: Registration information of thiencarbazone-methyl in Canada, as of April 2015
  • Table 1.10-4: Registration information of thiencarbazone-methyl in France, as of April 2015
  • Table 1.10-5: Registration information of thiencarbazone-methyl in Greece, as of April 2015
  • Table 1.10-6: Registration information of thiencarbazone-methyl in Switzerland, as of April 2015
  • Table 1.11-1: Patent information of topramezone in some countries/regions, as of April 2015
  • Table 1.11-2: Registration information of topramezone in Argentina, as of April 2015
  • Table 1.11-3: Registration information of topramezone in Belgium, as of April 2015
  • Table 1.11-4: Registration information of topramezone in Canada, as of April 2015
  • Table 1.11-5: Registration information of topramezone in Chile, as of April 2015
  • Table 1.11-6: Registration information of topramezone in China, as of April 2015
  • Table 1.11-7: Registration information of topramezone in Greece, as of April 2015
  • Table 1.11-8: Registration information of topramezone in the Netherlands, as of April 2015
  • Table 2.1-1: Patent information of bistrifluron in some countries/regions, as of April 2015
  • Table 2.1-2: Registration information of bistrifluron in Australia, as of April 2015
  • Table 2.2-1: Patent information of clothianidin in some countries/regions, as of April 2015
  • Table 2.2-2: Registration information of clothianidin in Argentina, as of April 2015
  • Table 2.2-3: Registration information of clothianidin in Australia, as of April 2015
  • Table 2.2-4: Registration information of clothianidin in Belgium, as of April 2015
  • Table 2.2-5: Registration information of clothianidin in Brazil, as of April 2015
  • Table 2.2-6: Registration information of clothianidin in Canada, as of April 2015
  • Table 2.2-7: Registration information of clothianidin in China, as of April 2015
  • Table 2.2-8: Registration information of clothianidin in Finland, as of April 2015
  • Table 2.2-9: Registration information of clothianidin in Greece, as of April 2015
  • Table 2.2-10: Registration information of clothianidin in the Netherlands, as of April 2015
  • Table 2.2-11: Registration information of clothianidin in Switzerland, as of April 2015
  • Table 2.2-12: Registration information of clothianidin in Uruguay, as of April 2015
  • Table 2.3-1: Patent information of ethiprole in some countries/regions, as of April 2015
  • Table 2.3-2: Registration information of ethiprole in China, as of April 2015
  • Table 2.4-1: Patent information of flubendiamide in some countries/regions, as of April 2015
  • Table 2.4-2: Registration information of flubendiamide in Australia as of April 2015
  • Table 2.4-3: Registration information of flubendiamide in Chile as of April 2015
  • Table 2.4-4: Registration information of flubendiamide in China, as of April 2015
  • Table 2.4-5: Registration information of flubendiamide in Greece as of April 2015
  • Table 2.4-6: Registration information of flubendiamide in the Netherlands as of April 2015
  • Table 2.4-7: Registration information of flubendiamide in Uruguay as of April 2015
  • Table 2.5-1: Patent information of metofluthrin in some countries/regions, as of April 2015
  • Table 2.5-2: Registration information of metofluthrin in Australia, as of April 2015
  • Table 2.5-3: Registration information of metofluthrin in Canada, as of April 2015
  • Table 2.5-4: Registration information of metofluthrin in China, as of April 2015
  • Table 2.5-5: Registration information of metofluthrin in the Netherlands, as of April 2015
  • Table 2.6-1: Patent information of pyridalyl in some countries/regions, as of April 2015
  • Table 2.6-2: Registration information of pyridalyl in China, as of April 2015
  • Table 2.6-3: Registration information of pyridalyl in the Netherlands, as of April 2015
  • Table 2.7-1: Patent information of pyrifluquinazon in some countries/regions, as of April 2015
  • Table 2.8-1: Patent information of spirotetramat in some countries/regions, as of April 2015
  • Table 2.8-2: Registration information of spirotetramat in Australia, as of April 2015
  • Table 2.8-3: Registration information of spirotetramat in Belgium, as of April 2015
  • Table 2.8-4: Registration information of spirotetramat in Canada, as of April 2015
  • Table 2.8-5: Registration information of spirotetramat in Chile, as of April 2015
  • Table 2.8-6: Registration information of spirotetramat in China, as of April 2015
  • Table 2.8-7: Registration information of spirotetramat in France, as of April 2015
  • Table 2.8-8: Registration information of spirotetramat in Greece, as of April 2015
  • Table 2.8-9: Registration information of spirotetramat in the Netherlands, as of April 2015
  • Table 2.8-10: Registration information of spirotetramat in Switzerland, as of April 2015
  • Table 3.1-1: Patent information of amisulbrom in some countries/regions, as of April 2015
  • Table 3.1-2: Registration information of amisulbrom in Belgium, as of April 2015
  • Table 3.1-3: Registration information of amisulbrom in Finland, as of April 2015
  • Table 3.1-4: Registration information of amisulbrom in the Netherlands, as of April 2015
  • Table 3.1-5: Registration information of amisulbrom in Switzerland, as of April 2015
  • Table 3.2-1: Patent information of benalaxyl-M in some countries/regions, as of April 2015
  • Table 3.2-2: Registration information of benalaxyl-M in Australia, as of April 2015
  • Table 3.2-3: Registration information of benalaxyl-M in Belgium, as of April 2015
  • Table 3.2-4: Registration information of benalaxyl-M in Brazil, as of April 2015
  • Table 3.2-5: Registration information of benalaxyl-M in Chile, as of April 2015
  • Table 3.2-6: Registration information of benalaxyl-M in France, as of April 2015
  • Table 3.2-7: Registration information of benalaxyl-M in Greece , as of April 2015
  • Table 3.2-8: Registration information of benalaxyl-M in the Netherlands, as of April 2015
  • Table 3.2-9: Registration information of benalaxyl-M in Switzerland, as of April 2015
  • Table 3.3-1: Patent information of benthiavalicarb-isopropyl in some countries/regions, as of April 2015
  • Table 3.3-2: Registration information of Benthiavalicarb-isopropyl in Belgium, as of April 2015
  • Table 3.3-3: Registration information of Benthiavalicarb-isopropyl in Greece, as of April 2015
  • Table 3.3-4: Registration information of Benthiavalicarb-isopropyl in the Netherlands, as of April 2015
  • Table 3.3-5: Registration information of Benthiavalicarb-isopropyl in Switzerland, as of April 2015
  • Table 3.4-1: Patent information of cyflufenamid in some countries/regions, as of April 2015
  • Table 3.4-2: Registration information of cyflufenamid in Australia, as of April 2015
  • Table 3.4-3: Registration information of cyflufenamid in Belgium, as of April 2015
  • Table 3.4-4: Registration information of cyflufenamid in Greece, as of April 2015
  • Table 3.4-5: Registration information of cyflufenamid in the Netherlands, as of April 2015
  • Table 3.4-6: Registration information of cyflufenamid in Switzerland, as of April 2015
  • Table 3.5-1: Patent information of dimoxystrobin in some countries/regions, as of April 2015
  • Table 3.5-2: Registration information of dimoxystrobin in Belgium, as of April 2015
  • Table 3.5-3: Registration information of dimoxystrobin in Denmark, as of April 2015
  • Table 3.5-4: Registration information of dimoxystrobin in France, as of April 2015
  • Table 3.6-1: Patent information of fluopicolide in some countries/regions, as of April 2015
  • Table 3.6-2: Registration information of fluopicolide in Argentina, as of April 2015
  • Table 3.6-3: Registration information of fluopicolide in Belgium, as of April 2015
  • Table 3.6-4: Registration information of fluopicolide in Brazil, as of April 2015
  • Table 3.6-5: Registration information of fluopicolide in Canada, as of April 2015
  • Table 3.6-6: Registration information of fluopicolide in Chile, as of April 2015
  • Table 3.6-7: Registration information of fluopicolide in China, as of April 2015
  • Table 3.6-8: Registration information of fluopicolide in Finland, as of April 2015
  • Table 3.6-9: Registration information of fluopicolide in France, as of April 2015
  • Table 3.6-10: Registration information of fluopicolide in Greece, as of April 2015
  • Table 3.6-11: Registration information of fluopicolide in the Netherlands, as of April 2015
  • Table 3.6-12: Registration infromation of fluopicolide in Switzerland, as of April 2015
  • Table 3.6-13: Registration information of fluopicolide in Uruguay, as of April 2015
  • Table 3.7-1: Patent information of fluoxastrobin in some countries/regions, as of April 2015
  • Table 3.7-2: Registration information of fluoxastrobin in Argentina, as of April 2015
  • Table 3.7-3: Registration information of fluoxastrobin in Belgium, as of April 2015
  • Table 3.7-4: Registration information of fluoxastrobin in Canada, as of April 2015
  • Table 3.7-5: Registration information of fluoxastrobin in France, as of April 2015
  • Table 3.7-6: Registration information of fluoxastrobin in the Netherlands, as of April 2015
  • Table 3.7-7: Registration information of fluoxastrobin in Switzerland, as of April 2015
  • Table 3.7-8: Registration information of fluoxastrobin in Uruguay, as of April 2015
  • Table 3.8-1: Patent information of isotianil in some countries/regions, as of April 2015
  • Table 3.9-1: Patent information of metalaxyl-M in some countries/regions, as of April 2015
  • Table 3.9-2: Registration information of metalaxyl-M in Australia, as of April 2015
  • Table 3.9-3: Registration information of metalaxyl-M in Belgium, as of April 2015
  • Table 3.9-4: Registration information of metalaxyl-M in Brazil, as of April 2015
  • Table 3.9-5: Registration information of metalaxyl-M in Canada, as of April 2015
  • Table 3.9-6: Registration information of metalaxyl-M in China, as of April 2015
  • Table 3.9-7: Registration information of metalaxyl-M in Finland, as of April 2015
  • Table 3.9-8: Registration information of metalaxyl-M in Greece, as of April 2015
  • Table 3.9-9: Registration information of metalaxyl-M in the Netherlands, as of April 2015
  • Table 3.9-10: Registration information of metalaxyl-M in South Africa, as of April 2015
  • Table 3.9-11: Registration information of metalaxyl-M in Switzerland, as of April 2015
  • Table 3.10-1: Patent information of metrafenone in some countries/regions, as of April 2015
  • Table 3.10-2: Registration information of metrafenone in Australia, as of April 2015
  • Table 3.10-3: Registration information of metrafenone in Belgium, as of April 2015
  • Table 3.10-4: Registration information of metrafenone in Canada, as of April 2015
  • Table 3.10-5: Registration information of metrafenone in Chile, as of April 2015
  • Table 3.10-6: Registration information of metrafenone in France, as of April 2015
  • Table 3.10-7: Registration information of metrafenone in Greece, as of April 2015
  • Table 3.10-8: Registration information of metrafenone in Switzerland, as of April 2015
  • Table 3.11-1: Patent information of orysastrobin in some countries/regions, as of April 2015
  • Table 3.12-1: Patent information of penthiopyrad in some countries/regions, as of April 2015
  • Table 3.12-2: Registration information of penthiopyrad in Australia, as of April 2015
  • Table 3.12-3: Registration information of penthiopyrad in France, as of April 2015
  • Table 3.13-1: Patent information of prothioconazole in some countries/regions, as of April 2015
  • Table 3.13-2: Registration information of prothioconazole in Argentina, as of April 2015
  • Table 3.13-3: Registration information of prothioconazole in Australia, as of April 2015
  • Table 3.13-4: Registration information of prothioconazole in Brazil, as of April 2015
  • Table 3.13-5: Registration information of prothioconazole in Canada, as of April 2015
  • Table 3.13-6: Registration information of prothioconazole in Finland, as of April 2015
  • Table 3.13-7: Registration information of prothioconazole in France, as of April 2015
  • Table 3.13-8: Registration information of prothioconazole in Greece, as of April 2015
  • Table 3.13-9: Registration information of prothioconazole in Switzerland, as of April 2015
  • Table 3.14-1: Patent information of pyraclostrobin in some countries/regions, as of April 2015
  • Table 3.14-2: Registration information of pyraclostrobin in Argentina, as of April 2015
  • Table 3.14-3: Registration information of pyraclostrobin in Australia, as of April 2015
  • Table 3.14-4: Registration information of pyraclostrobin in Belgium, as of April 2015
  • Table 3.14-5: Registration information of pyraclostrobin in Canada, as of April 2015
  • Table 3.14-6: Registration information of pyraclostrobin in China, as of April 2015
  • Table 3.14-7: Registration information of pyraclostrobin in Denmark, as of April 2015
  • Table 3.14-8: Registration information of pyraclostrobin in Finland, as of April 2015
  • Table 3.14-9: Registration information of pyraclostrobin in France, as of April 2015
  • Table 3.14-10: Registration information of pyraclostrobin in Greece, as of April 2015
  • Table 3.14-11: Registration information of pyraclostrobin in the Netherlands, as of April 2015
  • Table 3.14-12: Registration information of pyraclostrobin in South Africa, as of April 2015
  • Table 3.14-13: Registration information of pyraclostrobin in Switzerland, as of April 2015
  • Table 3.14-14: Registration information of pyraclostrobin in Uruguay, as of April 2015
  • Table 3.15-1: Patent information of silthiofam in some countries/regions, as of April 2015
  • Table 3.15-2: Registration information of silthiofam in Belgium, as of April 2015
  • Table 3.15-3: Registration information of silthiofam in China, as of April 2015
  • Table 3.15-4: Registration information of silthiofam in Denmark, as of April 2015
  • Table 3.15-5: Registration information of silthiofam in France, as of April 2015
  • Table 3.16-1: Patent information of valifenalate in some countries/regions, as of April 2015
  • Table 3.16-2: Registration information of valifenalate in Belgium, as of April 2015
  • Table 3.16-3: Registration information of valifenalate in France, as of April 2015
  • Table 3.16-4: Registration information of valifenalate in Switzerland, as of April 2015

List of Figures:

  • Figure 1.7-1: Synthesis route of pinoxaden
Back to Top